| early-onset parkinson's disease |
109 |
| next-generation sequencing |
109 |
| novel mutation |
109 |
| disease course |
118 |
| environmental factors |
118 |
| epidemiology |
118 |
| multiple sclerosis |
118, 142, 186, 213, 229 |
| progression |
118 |
| anxiety |
128 |
| depression |
128 |
| sleep bruxism |
128 |
| cerebrospinal fluid opening pressure |
133 |
| idiopathic intracranial hypertension |
133 |
| magnetic resonance imaging |
133 |
| optic nerve sheath diameter |
133 |
| pseudotumor cerebri |
133 |
| disability level |
142 |
| dual-task |
142 |
| functional mobility |
142 |
| manual dexterity |
142 |
| arrhythmia |
151 |
| heart rate variability |
151 |
| insula |
151 |
| stroke |
151, 159, 232 |
| sudden cardiac death |
151 |
| death |
159 |
| global burden of disease |
159 |
| prevalence |
159 |
| tobacco smoking |
159 |
| cognitive functions |
186 |
| radiologically isolated syndrome |
186 |
| bupivacaine |
196 |
| dexamethasone |
196 |
| greater occipital nerve block |
196 |
| medication-overuse headache |
196 |
| covid-19 |
213 |
| healthcare access |
213 |
| psychological health |
213 |
| dural arteriovenous fistula |
224 |
| indirect carotid cavernous fistula |
224 |
| posterior drainage carotid-cavernous fistula |
224 |
| alemtuzumab |
229 |
| anca-associated vasculitis |
229 |
| renal failure |
229 |
| diagnosis |
232 |
| ischemic stroke |
232 |
| takayasu arteritis |
232 |
